HC Wainwright & Co. Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $65
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $62 to $65.
HC Wainwright & Co. analyst Emily Bodnar maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $62 to $65.